Integrated BioTherapeutics
Highly Engaged Employees
Highly Engaged EmployeesChemicals & Related Products · Maryland, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
4 Research Ct Ste 300, Rockville, Maryla...Phone Number
(301) 515-0324Revenue
$9.3 MillionIndustry
About Integrated BioTherapeutics
IBT develops vaccines and immunotherapies for bacterial and viral infectious diseases. The Company's lead vaccine product, IBT-V02 is a first-in-class multi-component vaccine against Staphylococcus aureus. Supported by CARB-X and by Novo Holding's Repair Impact Fund, IBT-V02 is currently undergoing cGMP manufacturing and IND-enabling studies, with initiation of clinical trials anticipated in late 2022. IBT and its subsidiary IBV (http://www.integratedbiotherapeuticvaccines.com) immunotherapeutic pipeline includes monoclonal antibodies for the treatment of the array of viruses that cause hemorrhagic fever. IBT also is developing product candidates for the treatment of S. aureus, anthrax, and Clostridium difficile, based on its proprietary Infection Site Targeted Antitoxin Antibody (ISTAb) technology.Explore more
Integrated BioTherapeutics Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Integrated BioTherapeutics Tech Stack
A closer look at the technologies used by Integrated BioTherapeutics
See more technologies
Top Chemicals & Related Products Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Integrated BioTherapeutics
Sign Up For FreeTo access detailed company insights
IBT develops vaccines and immunotherapies for bacterial and viral infectious diseases. The Company's lead vaccine product, IBT-V02 is a first-in-class multi-component vaccine against Staphylococcus aureus. Supported by CARB-X and by Novo Holding's Repair Impact Fund, IBT-V02 is currently undergoing cGMP manufacturing and IND-enabling studies, with... Read More
